Diarrhoea is the second leading cause of death among children less than 5 years of age. Global Enteric Multicentre Study (GEMS) demonstrated that rotavirus was the most common etiology of moderate to severe diarrhoea (MSD) during the first 2 years of life. Montoring the impact and effectiveness of programmatic introduction of the rotavirus vaccine in The Gambia is a high priority.
The impact of vaccine introduction on the epidemiology of diarrheal diseases will likely extend beyond changes in rotavirus-associated morbidity and mortality alone; shifts in the predominant pathogens and adverse outcomes associated with MSD are also expected.
The study is utilizing the established GEMS infrastructure and methodology to conduct a 36-month case-control study of MSD in The Gambia to provide a detailed assessment of the changes in incidence, etiology, and adverse clinical outcomes of MSD that emerge now that the rotavirus vaccine is in use in The Gambia.
- Applications are invited from suitably qualified candidates for appointment as a Senior Scientific Officer for the Study. The post-holder will be based at MRC Falara and will be responsible for the molecular aspects of the VIDA study.
- S/he will be assigned other tasks within the molecular microbiology laboratory and will be required to assist with the management of other team members within the molecular microbiology laboratory.